When was MAIA founded?

MAIA was founded in 2018 and raised its 1st funding round 3 years after it was founded.

Where is MAIA located?

MAIA is headquartered in Chicago, United States.

Who is the current CEO of MAIA?

Vlad Vitoc Md of MAIA. They have also founded 1 company.

How many employees does MAIA have?

As of Jun 30, 2026, the latest employee count at MAIA is 26.

Is MAIA a funded company?

MAIA is a funded company, having raised a total of $8M across 11 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on May 19, 2021.

When was the latest funding round of MAIA?

MAIA's latest funding was a $***** Post IPO round on Dec 22, 2025, with participation from 0 investor.

Where does MAIA rank among its competitors?

MAIA ranks 89th amongst 2434 active competitors, of which 848 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Karyopharm, which secured $30M in Mar, 2026.

Who are the top competitors of MAIA?

MAIA's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Blueprint Medicines. Among them, Karyopharm secured the most recent funding round in March, 2026.

MAIA - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of immunotherapeutic solutions for cancer treatment. It offers telomere targeting agent MAIA and THIO for the treatment of multiple cancer by targeting and modifying telomeric structures of cancer cells through cancer-cell intrinsic telomerase activity.

Website: maiabiotech.com
Email ID: *****@maiabiotech.com
Phone Number: +1 **********

Key Metrics

Founded Year

2018

Location

Chicago, United States

Stage

Public

Total Funding

$8M in 11 rounds

Latest Funding Round

Post IPO, Dec 22, 2025, $*****

Investors

BRK Financial Group & 3 more

Ranked

89^th among 2434 active competitors

Employee Count

26 as on Jun 30, 2026

Similar Companies

Inotrem & 57 more

Exit Details

Public

View MAIA's full profile

MAIA is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
MAIA BIOTECHNOLOGY, INC. CIN: 1878313 , United States, Active	Aug 02, 2018	-	-	-
MAIA Biotechnology Inc CIN: 83-1495913 , United States, Active	Dec 31, 2017	-	18 (As on Dec 31, 2022)	-

MAIA got listed on Jul 28, 2022.

Click here to take a look at MAIA's IPO in detail

MAIA has raised a total funding of $8M over 11 rounds. Its first funding round was on May 19, 2021. MAIA has 4 institutional investors.

Here is the list of recent funding rounds of MAIA:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 22, 2025	5813603	Post IPO	9124667	5593730	8712054	3497198
Sep 29, 2025	4460891	Post IPO	3940600	5161988	5288535	2751657
Sep 08, 2025	9941396	Grant (prize money)	4515843	5288487	8995091	HHS

Access funding benchmarks and valuations. Sign up today!

View details of MAIA's funding rounds and investors

The founders of MAIA is Vlad Vitoc Md.

Here are the details of MAIA's key team members:

Vlad Vitoc Md: Founder and CEO of MAIA.
Contact Info: 1 email address

View details of MAIA's Founder profiles and Board Members

MAIA's employee count trend

MAIA has 26 employees as of Jun 26. Here is MAIA's employee count trend over the years:

Uncover MAIA's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of MAIA include Jazz Pharmaceuticals, Sana Biotechnology and Blueprint Medicines. Here is the list of Top 10 competitors of MAIA, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	KKR, Versant Ventures & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Bezos Expeditions & 17 others	75/100
3rd	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Google Ventures & 15 others	72/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, SV Health Investors & 17 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Delos Capital Partners ... & 19 others	72/100
7th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Avidity Partners, Foresite Capital & 16 others	71/100
8th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
9th	Zymeworks 2003, Vancouver (Canada), Public	Developer of bi-specific antibodies & antibody-drug conjugates to treat cancer	$146M	CTI Life Sciences Fund, Advanced Biotechnologies Venture Fund ... & 16 others	71/100
10th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	71/100
89th	MAIA 2018, Chicago (United States), Public	Developer of immunotherapeutic solutions for cancer treatment	$8M	HHS, BRK Financial Group & 2 others	62/100